BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+3.83%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.15B
AUM Growth
+$6.15B
(-6.1%)
Cap. Flow
-$279M
Cap. Flow
% of AUM
-4.53%
Top 10 Holdings %
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
65
Reduced
60
Closed
12
Top Buys
| 1 |
Stryker
SYK
|
$32.9M |
| 2 |
Biohaven
BHVN
|
$30.9M |
| 3 |
UnitedHealth
UNH
|
$29M |
| 4 |
Insulet
PODD
|
$28.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$26.5M |
Top Sells
| 1 |
Insmed
INSM
|
$75M |
| 2 |
Intuitive Surgical
ISRG
|
$63.3M |
| 3 |
argenx
ARGX
|
$51.2M |
| 4 |
Boston Scientific
BSX
|
$44.6M |
| 5 |
Humana
HUM
|
$40M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Industrials | 0.05% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.02% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Globus Medical
GMED
$7.94B
| $34.1M | 0.55% |
497,293
-82,605
| -14% | -$5.66M |
|
|
52
Regeneron Pharmaceuticals
REGN
$59.8B
| $33.9M | 0.55% |
32,297
+25,220
| +356% | +$26.5M |
|
53
CRISPR Therapeutics
CRSP
$4.82B
| $33.4M | 0.54% |
617,649
-2,301
| -0.4% | -$124K |
|
54
Beam Therapeutics
BEAM
$1.9B
| $33.2M | 0.54% |
1,418,121
+225,000
| +19% | +$5.27M |
|
55
Evolent Health
EVH
$1.11B
| $31.9M | 0.52% |
1,669,835
+186,739
| +13% | +$3.57M |
|
56
Veeva Systems
VEEV
$44.4B
| $30.9M | 0.5% |
168,583
+336
| +0.2% | +$61.5K |
|
57
Transmedics
TMDX
$3.65B
| $30.3M | 0.49% |
201,415
-162,649
| -45% | -$24.5M |
|
58
ResMed
RMD
$39.4B
| $29.8M | 0.48% |
155,881
+125,490
| +413% | +$24M |
|
59
Centene
CNC
$14.8B
| $27.9M | 0.45% |
421,458
+58,358
| +16% | +$3.87M |
|
60
McKesson
MCK
$85.9B
| $26.9M | 0.44% |
46,142
+37,145
| +413% | +$21.7M |
|
61
Castle Biosciences
CSTL
$673M
| $26.5M | 0.43% |
1,217,101
-2,984
| -0.2% | -$65K |
|
62
Edgewise Therapeutics
EWTX
$1.54B
| $25.7M | 0.42% |
+1,428,929
| New | +$25.7M |
|
63
Annexon
ANNX
$225M
| $25.3M | 0.41% |
5,157,290
+2,975,000
| +136% | +$14.6M |
|
64
Thermo Fisher Scientific
TMO
$183B
| $23.6M | 0.38% |
42,626
+2,670
| +7% | +$1.48M |
|
65
Natera
NTRA
$23B
| $23.2M | 0.38% |
213,987
-55,845
| -21% | -$6.05M |
|
|
SILK
66
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $23.1M | 0.38% |
855,293
-662,937
| -44% | -$17.9M |
|
67
Molina Healthcare
MOH
$9.6B
| $22.7M | 0.37% |
76,393
-23,490
| -24% | -$6.98M |
|
68
Esperion Therapeutics
ESPR
$490M
| $22.1M | 0.36% |
9,944,064
| – | – |
|
69
Structure Therapeutics
GPCR
$1.14B
| $21.9M | 0.36% |
557,321
+193,395
| +53% | +$7.59M |
|
70
Danaher
DHR
$143B
| $21M | 0.34% |
83,920
-2,312
| -3% | -$578K |
|
71
Wave Life Sciences
WVE
$1.27B
| $20.4M | 0.33% |
4,094,458
| – | – |
|
72
Cencora
COR
$57.2B
| $20.1M | 0.33% |
89,329
-42,175
| -32% | -$9.5M |
|
73
Steris
STE
$23.9B
| $20M | 0.33% |
91,282
+17,848
| +24% | +$3.92M |
|
74
HUTCHMED
HCM
$2.62B
| $19.7M | 0.32% |
1,149,157
-5,475
| -0.5% | -$93.7K |
|
75
IQVIA
IQV
$31.4B
| $19.5M | 0.32% |
92,083
+83,747
| +1,005% | +$17.7M |
|